Analysts predict that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will report earnings of ($0.45) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Xenon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.43). Xenon Pharmaceuticals also reported earnings per share of ($0.45) in the same quarter last year. The company is scheduled to issue its next earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Xenon Pharmaceuticals will report full year earnings of ($1.88) per share for the current year, with EPS estimates ranging from ($1.99) to ($1.76). For the next fiscal year, analysts expect that the business will report earnings of ($1.75) per share, with EPS estimates ranging from ($1.90) to ($1.60). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.06).
Shares of Xenon Pharmaceuticals stock traded up $0.11 during trading on Friday, reaching $10.16. The company’s stock had a trading volume of 47,899 shares, compared to its average volume of 60,488. The stock has a market capitalization of $261.85 million, a P/E ratio of -7.64 and a beta of 1.33. The company has a debt-to-equity ratio of 0.18, a quick ratio of 17.57 and a current ratio of 17.57. The company has a 50-day moving average price of $9.79. Xenon Pharmaceuticals has a 1-year low of $5.41 and a 1-year high of $15.92.
Hedge funds have recently modified their holdings of the stock. Sphera Funds Management LTD. raised its stake in shares of Xenon Pharmaceuticals by 18.7% during the 1st quarter. Sphera Funds Management LTD. now owns 533,655 shares of the biopharmaceutical company’s stock valued at $5,422,000 after buying an additional 84,171 shares during the last quarter. D. E. Shaw & Co. Inc. purchased a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at about $828,000. venBio Select Advisor LLC raised its stake in shares of Xenon Pharmaceuticals by 1.4% during the 4th quarter. venBio Select Advisor LLC now owns 2,400,000 shares of the biopharmaceutical company’s stock valued at $15,144,000 after buying an additional 32,782 shares during the last quarter. Scotia Capital Inc. raised its stake in shares of Xenon Pharmaceuticals by 16.8% during the 4th quarter. Scotia Capital Inc. now owns 66,704 shares of the biopharmaceutical company’s stock valued at $421,000 after buying an additional 9,618 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Xenon Pharmaceuticals by 18.9% during the 4th quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,948 shares during the last quarter. Institutional investors own 68.83% of the company’s stock.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.
Featured Story: Why Net Income is Important to Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.